SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 2

Intravitreal Aflibercept Injection and Treatment Regimens in Macular Edema Due to Branch Retinal Vein Occlusion

Retinal Ven Dal Tıkanıklığına Bağlı Maküla Ödeminde İntravitreal Aflibercept Enjeksiyonu ve Tedavi Protokolleri

Mehmet Orkun SEVİK
Özlem ŞAHİN
Pages
92–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the studies about the use of aflibercept in different regimens for the treatment of macular edema due to BRVO.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Branch retinal vein occlusion (BRVO) is the most common form of retinal vein occlusions (RVO), which is the second most common retinal vascular disease after diabetic retinopathy.
📊
Key Findings & Data:The most common cause of visual loss in BRVO is macular edema.
💡
Conclusion & Impact:This review summarizes the studies about the use of aflibercept in different regimens for the treatment of macular edema due to BRVO.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Branch retinal vein occlusion (BRVO) is the most common form of retinal vein occlusions (RVO), which is the second most common retinal vascular disease after diabetic retinopathy. The most common cause of visual loss in BRVO is macular edema. Since the vascular endothelial growth factor (VEGF) was detected in the pathogenesis of macular edema due to BRVO, studies have been made with available anti-VEGF agents and different treatment regimens. Those treatment regimens can be listed as; “monthly / bimonthly fixed intervals”, “as needed” (Pro Re Nata; PRN), “treat and extend” (T&E). Aflibercept acts as a decoy receptor that binds to VEGF-A, VEGF-B and placental growth factor. There are publications indicating that this agent binds VEGF with a higher affinity than other anti-VEGF agents and thus provides a longer treatment efficacy. This review summarizes the studies about the use of aflibercept in different regimens for the treatment of macular edema due to BRVO.

Özet

Retinal ven dal tıkanıklığı (RVDT), diyabetik retinopatiden sonra en sık görülen ikinci retinal vasküler hastalık olan retinal ven tıkanıklıklarının (RVT) en sık görülen formudur. RVDT’de görme kaybının en sık sebebi maküler ödemdir. RVDT’ye bağlı maküler ödemin patogenezinde vasküler endotelyal büyüme faktörü (VEGF) olduğunun saptanması üzerine, tedavide mevcut anti-VEGF ajanlarla ve farklı tedavi protokolleri ile çalışmalar yapılmıştır. Bu tedavi protokolleri; “ayda bir / iki ayda bir sabit aralıklı uygulama”, “gerektikçe uygulama” (Pro Re Nata; PRN), “tedavi et ve uzat” (Treat And Extend; T&E) olarak sıralanabilir. Aflibercept, VEGF-A, VEGF-B ve plasental büyüme faktörüne bağlanan bir tuzak reseptör olarak çalışır. Bu ajanın VEGF’e diğer anti-VEGF ajanlardan daha yüksek afiniteyle bağlandığı ve bu nedenle daha uzun süre tedavi etkinliği sağladığını belirten yayınlar mevcuttur. Bu derlemede, afliberceptin, RVDT’ye bağlı maküler ödem tedavisinde farklı tedavi protokollerinde kullanımı ile ilgili çalışmalar özetlenmektedir

🔖

Cite This Article

SEVİK, M. O., ŞAHİN, Ö. (2019). Intravitreal Aflibercept Injection and Treatment Regimens in Macular Edema Due to Branch Retinal Vein Occlusion. Güncel Retina Dergisi, Cilt: 3 - Sayı: 2, 92–98. https://ajindex.com/articles/204345

References (12)

  1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-518
  2. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: Epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33(5):901-910
  3. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC et al. Risk factors for hemiretinal vein occlusion: Comparison with risk factors for central and branch retinal vein occlusion: The eye disease case-control study. Ophthalmology. 1998;105(5):765-771
  4. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: An approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38(12):904-910
  5. Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol. 2011;152(4):669-677. e661
  6. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795-802
  7. Wroblewski JJ, Wells JA, 3rd, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149(1):147-154
  8. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina. 2011;31(9):1856-1862
  9. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1101
  10. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544
  11. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032
  12. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G et al. Vegf trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of t